Deciphering the Role of Oxytocin in Motivation: an fMRI Study

• Status: Completed
• Trial end date: 2015-10-01
• Target enrollment: 0
• Participant gender: Male

Summary

The proposed study will investigate the effects of intranasal oxytocin administration on neural activity associated with social and non-social motivation.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Tiffany Love
• Collaborator: University of Michigan
• Treatments: Oxytocin

Criteria

Inclusion Criteria:

• Male

• 20-35 years of age at the time of screening

• Right-handedness

• Non-smoking

• No current or past history of neurological or psychiatric illness, including substance abuse or dependence

• No acute medical illness

• Written informed consent obtained from subject

Exclusion Criteria:

• Female

• Left-handedness or ambidextrous

• Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data

• Known allergies to oxytocin or to preservatives in the nasal spray

• Participants who exhibit nasal obstruction or upper-respiratory tract infection at the time of scanning or report the use of intranasally administered medications for up to two weeks prior to screening

• Participants unable to tolerate the scanning procedures or would be unfit for scanning purposes (e.g. metal implants, claustrophobic, unable to lie still for the duration of the scan)

• Any current or past history of medical, neurological, or psychiatric illness or family history of psychiatric or neurologic disease in first-degree relatives

• Neurological illness, abnormal MRI (except if due to technical factors)

• Acute or uncorrected medical illnesses, including history of hepatic or renal dysfunction.

• Participants currently taking medications including any treatment, current or past with antipsychotics, mood stabilizers, isoniazid, glucocorticoids, psychostimulants and psychostimulant appetite suppressants, or centrally active antihypertensive drugs (e.g., clonidine, reserpine).

• Treatment within six months with any of the following: hormone use (testosterone, DHEA), antidepressants, opioid drugs.

• Treatment within one month with sedative hypnotic medications (benzodiazepines, barbiturates), or over the counter sleeping aids

• Current or past history of substance abuse or dependence

• Any reported lifetime use of any category of illicit drugs

• Positive urine drug screen